To include your compound in the COVID-19 Resource Center, submit it here.

PharmaMar reports Phase II response data for Zepsyre in Ewing's sarcoma

PharmaMar S.A. (Madrid:PHM) reported data from 25 patients with Ewing’s sarcoma who received ≤2 prior chemotherapeutic treatments in a Phase II trial showing that 3.2 mg/m2

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE